Cover Image
市場調查報告書

痛風的預測:主要15大市場

Gout Forecast in 15 Major Markets 2015-2025

出版商 Black Swan Analysis 商品編碼 339838
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
痛風的預測:主要15大市場 Gout Forecast in 15 Major Markets 2015-2025
出版日期: 2015年09月01日 內容資訊: 英文 74 Pages
簡介

痛風是由於關節內尿酸積蓄所引起。

本報告提供主要15大市場 (美國,法國,德國,義大利,西班牙,英國,巴西,日本,加拿大,澳洲,荷蘭,捷克,希臘,印度,墨西哥) 的痛風之目前患者數 (性別,年齡世代別) 調查分析,提供您目前得病率,加上疾病概要,危險因素,疾病診斷與預後,主要的症狀和併發症等系統性資訊。

圖表

簡介

病因

危險因素和預防

疾病診斷

變異:地區/各民族

疾病預後與臨床經過

疾病相關的主要併發症/特徵

患者數定量化手法

  • 追加資料

痛風的得病率top line

過去12個月有發炎經驗的痛風患者特徵

  • 過去12個月的發炎頻率
  • 發炎中的痛風患者之關節障礙
  • 痛風患者的腎功能與特徵

最初表現時的痛風患者特徵

痛風相關的併發症

打結性痛風

簡稱

相關出版

患者基群線上資料庫

患者基群產品

價格的線上資料·平台

參考文獻

附錄

目錄
Product Code: GOUT0010915

Gout is caused by the build up of uric acid in the joints due to the body producing too much or excreting too little in the urine, and develops into sodium urate crystals. The formation of these crystals causes pain and inflammation around bone joints. The majority of Gout attacks involve the first metatarsophalangeal joint (FMJ) which is the "big toe" (also known as podagra). Gout can also occur in other joints of the body such as the spine, other parts of the foot, hips or shoulders and hands.

This report provides the current prevalent population for Gout across 15 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Canada, Australia, Netherlands, Czech Republic, Greece, India and Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the frequency of Gout flares, joint involvement, kidney function and presence of tophi in Gout. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Gout have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Gout include:

  • Obesity and weight gain
  • Kidney stones, renal cysts and renal failure
  • Coronary artery disease, Chronic Heart Failure
  • Hypertension
  • Dyslipidaemia
  • Diabetes mellitus
  • Metabolic syndrome
  • Hyperuricaemia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Gout's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Gout and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Gout's prevalent population.
  • Identify sub-populations within Gout which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Gout patients.

Coverage

US, UK, FR, DE, IT, ES, JP, BR, IN

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis &Clinical Course

Key Co-morbid Conditions /Features Associated with the Disease

Methodology for Quantification of Patient Numbers

  • Additional data available on request

Top-Line Prevalence for Gout

Features of Gout Patients Experiencing Flare in Past 12 Months

  • Frequency of Flare in past 12 months
  • Joint Involvement in Gout patients during Flare
  • Kidney Function and Features in patients with Gout

Features of Gout Patients at Initial Presentation

Associated Co-morbid Conditions of Gout

Tophaceous Gout

Abbreviations used in the Report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Figures

  • ACR criteria for diagnosis of Gout
  • ROME criteria for diagnosis of Gout
  • New York criteria for diagnosis of Gout

List of Tables

  • Prevalence of Gout, total (000s)
  • Prevalence of Gout, males (000s)
  • Prevalence of Gout, females (000s)
  • Gout patients with at least one flare in the past 12 months, total (000s)
  • Number of flares in past 12 months, total (000s)
  • Location of affected joint in patients with Gout flare, total (000s)
  • The extent of joint involvement in patients during Gout flare, total (000s)
  • eGFR status of patients with Gout, total (000s)
  • Prevalence of Renal Cysts in patients with Gout, total (000s)
  • Prevalence of Nephrolithiasis in patients with Gout, total (000s)
  • Estimated annual incidence of Gout, total (000s)
  • Body Mass Index of patients with Gout at initial presentation, total (000s)
  • Gout patients with a family history of Gout, total (000s)
  • Uric acid level at presentation for patients with Gout, total (000s)
  • Diabetes Mellitus in patients with Gout, total (000s)
  • Dyslipidaemia in patients with Gout, total (000s)
  • Prevalence of Hypertension in patients with Gout, total (000s)
  • Hyperuricaemia in patients with Gout, total (000s)
  • Metabolic Syndrome in patients with Gout, total (000s)
  • Osteoarthritis in patients with Gout, total (000s)
  • Peripheral Artery Disease in patients with Gout, total (000s)
  • Presence of tophi in patients with Gout, total (000s)
  • Patients with tophi by number present, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Gout by 5-yr age cohort, males (000s)
  • USA Prevalence of Gout by 5-yr age cohort, females (000s)
  • France Prevalence of Gout by 5-yr age cohort, males (000s)
  • France Prevalence of Gout by 5-yr age cohort, females (000s)
  • Germany Prevalence of Gout by 5-yr age cohort, males (000s)
  • Germany Prevalence of Gout by 5-yr age cohort, females (000s)
  • Italy Prevalence of Gout by 5-yr age cohort, males (000s)
  • Italy Prevalence of Gout by 5-yr age cohort, females (000s)
  • Spain Prevalence of Gout by 5-yr age cohort, males (000s)
  • Spain Prevalence of Gout by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of Gout by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of Gout by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Gout by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Gout by 5-yr age cohort, females (000s)
  • Japan Prevalence of Gout by 5-yr age cohort, males (000s)
  • Japan Prevalence of Gout by 5-yr age cohort, females (000s)
  • Canada Prevalence of Gout by 5-yr age cohort, males (000s)
  • Canada Prevalence of Gout by 5-yr age cohort, females (000s)
  • Australia Prevalence of Gout by 5-yr age cohort, males (000s)
  • Australia Prevalence of Gout by 5-yr age cohort, females (000s)
  • Netherlands Prevalence of Gout by 5-yr age cohort, males (000s)
  • Netherlands Prevalence of Gout by 5-yr age cohort, females (000s)
  • Czech Republic Prevalence of Gout by 5-yr age cohort, males (000s)
  • Czech Republic Prevalence of Gout by 5-yr age cohort, females (000s)
  • Greece Prevalence of Gout by 5-yr age cohort, males (000s)
  • Greece Prevalence of Gout by 5-yr age cohort, females (000s)
Back to Top